Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented new preclinical data from its immuno-oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, including one oral and two poster sessions. The data featured TNX-1700 and TNX-4700, two candidates that could address significant unmet needs in cancer treatment.
TNX-1700, a novel biologic, demonstrated potential in reducing inflammation and tumor progression in preclinical models of gastric cancer. The compound also showed favorable pharmacokinetics, suggesting it may be suitable for further clinical development. Gastric cancer remains a challenging malignancy with limited treatment options, making these findings particularly relevant for patients and clinicians seeking new therapies.
TNX-4700, meanwhile, exhibited promising in vitro activity targeting BTLA (B- and T-lymphocyte attenuator), an immune checkpoint receptor. As a cancer immunotherapy candidate, TNX-4700 could be used alone or in combination with other checkpoint inhibitors, potentially offering a new approach to reactivate anti-tumor immune responses. The company emphasized that these data support the continued advancement of its immuno-oncology pipeline.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. The company’s recently approved flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in over 15 years. Tonix’s CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra. The company is exploring TONMYA’s potential in Phase 2 trials for major depressive disorder and acute stress disorder.
Beyond immuno-oncology, Tonix’s pipeline includes TNX-2900, Phase 2 ready for Prader-Willi syndrome, and immunology programs such as TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection. These programs highlight the company’s commitment to addressing high unmet medical needs across multiple therapeutic areas.
The presentation of these data at AACR 2026 underscores Tonix’s progress in immuno-oncology and its broader strategy to leverage scientific insights for novel therapeutics. For more information on the company and its pipeline, visit the Tonix newsroom at https://ibn.fm/TNXP.
